Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

(; now ) is an infectious agent that causes severe arthritis in swines and shares sequence similarity with residues 261-273 of collagen type 2 (Coll), a possible autoantigen in rheumatoid arthritis (RA). We tested the presence of sequencing 16S ribosomal RNA in crevicular fluid, synovial fluids, and tissues in patients with arthritis (RA and other peripheral arthritides) and in healthy controls. Moreover, we examined the cross-recognition of by Coll-specific T cells in HLA-DRB104 RA patients, by T-cell receptor (TCR) beta chain spectratyping and T-cell phenotyping. DNA was present in 57.4% of the tooth crevicular fluids of RA patients and in 31.6% of controls. Anti- IgM and IgG titers were detectable and correlated with disease duration and the age of the patients. Peripheral blood mononuclear cells (PBMCs) were stimulated with virulence-associated trimeric autotransporter peptide (VtaA10), homologous to human Coll or co-cultured with live . In both conditions, the expanded TCR repertoire overlapped with Coll and led to the production of IL-17. We show that the DNA of an infectious agent (), not previously described as pathogen in humans, is present in most patients with RA and that an peptide is able to activate T cells specific for Coll, likely inducing or maintaining a molecular mimicry mechanism. The cross-reactivity between VtaA10 of a non-human infectious agent and human Coll suggests an involvement in the pathogenesis of RA. This mechanism appears emphasized in predisposed individuals, such as patients with shared epitope.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415917PMC
http://dx.doi.org/10.3389/fmed.2021.671018DOI Listing

Publication Analysis

Top Keywords

infectious agent
12
molecular mimicry
8
rheumatoid arthritis
8
human coll
8
patients
6
coll
5
potential driver
4
driver molecular
4
mimicry inflammation
4
inflammation rheumatoid
4

Similar Publications

Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.

Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.

View Article and Find Full Text PDF

Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway.

View Article and Find Full Text PDF

Recently, to achieve cure, physicians have been resorting to overuse or misuse of antimicrobials to treat resistant infections, leading to the emergence of further resistant organisms. To overcome this issue, antimicrobial guidelines have been developed. Nevertheless, recently, controversy regarding the effect of adherence to antimicrobial guidelines on patient outcomes has been raised.

View Article and Find Full Text PDF

Background: Mucormycosis is a rare, rapidly progressive fungal infection with a high mortality rate. However, clinical data of mucormycosis patients, especially those related to adverse outcomes in China, remain limited.

Objective: To enhance understanding of the clinical characteristics of different infection site mucormycosis and identify the factors associated with adverse outcomes.

View Article and Find Full Text PDF

Cytomegalovirus (CMV) infection poses significant challenges in solid organ transplant (SOT) recipients, impacting graft outcomes, morbidity, and in some cases survival. The ESOT CMV Workshop 2023 convened European experts to discuss current practices and advances in the management of CMV with the aim of improving the quality of life of transplant recipients. Discussions covered crucial areas such as preventive strategies, diagnostic challenges, therapeutic approaches, and the role of cell-mediated immunity (CMI) monitoring.

View Article and Find Full Text PDF